Tumor necrosis factor-␣ (TNF␣) is involved in the physiological and biological abnormalities found in two opposite metabolic situations: cachexia and obesity. In an attempt to identify novel genes and proteins that could mediate the effects of TNF␣ on adipocyte metabolism and development, we have used a differential display technique comparing 3T3-L1 cells exposed or not to the cytokine. We have isolated a novel adipose cDNA encoding a TNF␣-inducible 470-amino acid protein termed TIARP, with six putative transmembrane regions flanked by a large amino-terminal and a short carboxyl-terminal domain, a structure reminiscent of channel and transporter proteins. Commitment into the differentiation process is required for cytokine responsiveness. The differentiation process per se is accompanied by a sharp emergence of TIARP mRNA transcripts, in parallel with the expression of the protein at the plasma membrane. Transcripts are present at high levels in white and brown adipose tissues, and are also detectable in liver, kidney, heart, and skeletal muscle. Whereas the biological function of TIARP is presently unknown, its pattern of expression during adipose conversion and in response to TNF␣ exposure as a transmembrane protein mainly located at the cell surface suggest that TIARP might participate in adipocyte development and metabolism and mediate some TNF␣ effects on the fat cell as a channel or a transporter. Tumor necrosis factor-alpha (TNF␣)1 exerts a wide range of effects on cells and tissues. In addition to its immunological functions, TNF␣ also markedly alters adipose tissue development and metabolism. Surprisingly, TNF␣ seems to be involved in the pathophysiology of two opposite metabolic disorders (1). High plasma levels of TNF␣ likely play an important role in the onset of cachectic states observed during cancer or severe infectious diseases (2). By contrast, more recent studies have indicated that the cytokine is overexpressed in adipose tissue of obese rodents or humans, and that this locally produced TNF␣ may be involved in the obesity-linked insulin resistance (3). Thus, since abnormalities in its production or action are associated with alterations in body fat mass, TNF␣ is likely an important effector of adipose tissue development and metabolism in vivo.Many in vitro studies also support the view that TNF␣ has profound effects on lipid metabolism and adipocyte differentiation. TNF␣ was reported to inhibit lipid storage by reducing synthesis and activity of several proteins essential for lipogenesis, such as lipoprotein lipase (4) and acetyl-coenzyme A carboxylase (5), or by inhibition in the expression and/or function of the insulin-sensitive glucose transporter GLUT4 pathway (6). Otherwise TNF␣ is able to stimulate lipolysis in adipocytes by different mechanisms (7,8). In addition to the above effects on lipid storage or mobilization, TNF␣ potently inhibits adipose conversion and even causes a dramatic de-differentiation of adipocytes in culture (9). Prevention of adipose conversion by TNF␣ has been es...

Gastric carcinoma is the third leading cause of cancer-related death worldwide. This cancer, most of the time metastatic, is essentially treated by surgery associated with conventional chemotherapy, and has a poor prognosis. The existence of cancer stem cells (CSC) expressing CD44 and a high aldehyde dehydrogenase (ALDH) activity has recently been demonstrated in gastric carcinoma and has opened new perspectives to develop targeted therapy. In this study, we evaluated the effects of all-trans-retinoic acid (ATRA) on CSCs in human gastric carcinoma. ATRA effects were evaluated on the proliferation and tumorigenic properties of gastric carcinoma cells from patient-derived tumors and cell lines in conventional 2D cultures, in 3D culture systems (tumorsphere assay) and in mouse xenograft models. ATRA inhibited both tumorspheres initiation and growth in vitro, which was associated with a cell-cycle arrest through the upregulation of cyclin-dependent kinase (CDK) inhibitors and the downregulation of cell-cycle progression activators. More importantly, ATRA downregulated the expression of the CSC markers CD44 and ALDH as well as stemness genes such as Klf4 and Sox2 and induced differentiation of tumorspheres. Finally, 2 weeks of daily ATRA treatment were sufficient to inhibit gastric tumor progression in vivo, which was associated with a decrease in CD44, ALDH1, Ki67 and PCNA expression in the remaining tumor cells. Administration of ATRA appears to be a potent strategy to efficiently inhibit tumor growth and more importantly to target gastric CSCs in both intestinal and diffuse types of gastric carcinoma.